Skip to main content

Table 3 Pharmacological treatments and radiotherapy in HER2 positive Breast Cancer Patients

From: Frequency and clinical characteristics of HER2 over-expressed breast cancer in Saudi Arabia: a retrospective study

  n (%)
Pharmacological treatment setting from diagnosis till end of data collection (cut-off point), n = 309
Neoadjuvant only 10 (3.2%)
Adjuvant only 134 (43.4%)
Metastatic only 46 (14.9%)
Neoadjuvant + Adjuvant + Metastatic 22 (7.1%)
Neoadjuvant + Adjuvant 74 (23.9%)
Adjuvant + Metastatic 19 (6.1%)
Neoadjuvant treatment regimens, n = 110
Neoadjuvant + Metastatic 4 (1.3%)
Hormonotherapy alone 3 (2.7%)
Chemotherapy alone 83 (75.5%)
Trastuzumab alone 7 (6.4%)
Chemotherapy + Trastuzumab 87 (79.1%)
Other regimens 2 (1.8%)
Adjuvant treatment regimens, n = 249
Hormonotherapy alone 140 (56.2%)
Chemotherapy alone 113 (45.4%)
Trastuzumab alone 96 (38.6%)
Chemotherapy + Trastuzumab 129 (51.8%)
Hormonotherapy + Trastuzumab 22 (8.8%)
Metastatic treatment regimens, n = 91
Hormonotherapy alone 41 (45.1%)
Chemotherapy alone 40 (44.0%)
Targeted therapy alone 36 (45.1%)
Chemotherapy + Targeted therapy 59 (64.8%)
Hormonotherapy + Targeted therapy 14 (15.4%)
Hormonotherapy + Chemotherapy + Targeted therapy 2 (3.3%)
Radiotherapy, n = 347
No 98 (28.2%)
Yes 249 (71.8%)